Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress
WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that seven abstracts will be presented at the hybrid European Hematology Association (EHA) Congress to be held June 9-12 in Vienna, Austria. Data to be presented reinforce the robust efficacy and safety profile of EMPAVELI® (pegcetacoplan) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
“Our presence at EHA this year continues to underscore the potential of EMPAVELI to become the new standard of care for all adults living with PNH,” said Federico Grossi, M.D., Ph.D., chief medical officer of Apellis.
About EMPAVELI®/Aspaveli® (pegcetacoplan)
U.S. Important Safety Information for EMPAVELI
BOXED WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA
WARNINGS AND PRECAUTIONS
Serious Infections Caused by Encapsulated Bacteria
For patients without known history of vaccination, administer required vaccines at least 2 weeks prior to receiving the first dose of EMPAVELI. If immediate therapy with EMPAVELI is indicated, administer required vaccine as soon as possible and provide patients with 2 weeks of antibacterial drug prophylaxis.
Closely monitor patients for early signs and symptoms of serious infection and evaluate patients immediately if an infection is suspected. Promptly treat known infections. Serious infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider discontinuation of EMPAVELI in patients who are undergoing treatment for serious infections.
Monitoring PNH Manifestations after Discontinuation of EMPAVELI
Interference with Laboratory Tests
USE IN SPECIFIC POPULATIONS
About Paroxysmal Nocturnal Hemoglobinuria (PNH)
About the Apellis and Sobi Collaboration
Apellis Forward-Looking Statement